Gal α(1, 3) Gal (gal epitope) is a carbohydrate epitope and synthesized in large amount by α(1, 3) galactosyltransferase [α(1, 3) GT] enzyme on the cells of lower mammalian animals such as pigs and mice. Human has no gal epitope due to the inactivation of α(1, 3) GT gene but produces a large amount of antibodies (anti-Gal) which recognize Gal α(1, 3) Gal structures specifically. In this study, a replication-deficient recombinant adenoviral vector Ad5sGT containing pig α(1, 3) GT cDNA was constructed and characterized. Adenoviral vector-mediated transfer of pig α(1, 3) GT gene into human tumor cells such as malignant melanoma A375, stomach cancer SGC-7901, and lung cancer SPC-A-1 was reported for the first time. Results showed that Gal epitope did not increase the sensitivity of human tumor cells to human complement-mediated lysis, although human complement activation and the binding of human IgG and IgM natural antibodies to human tumor cells were enhanced significantly after Ad5sGT transduction. Appearance of gal epitope on the human tumor cells changed the expression of cell surface carbohydrates reacting with Ulex europaeus I (UEA I) lectins, Vicia villosa agglutinin (VVA), Arachis hypogaea agglutinin (PNA), and Glycine max agglutinin (SBA) to different degrees. In addition, no effect of gal epitope on the growth in vitro of human tumor cells was observed in MTT assay.
INTRODUCTION
Gal α(1, 3) Gal (gal epitope) is a carbohydrate epitope, which is produced in large amount on the cells of pigs, mice and New World monkey (monkey of South America) by the glycosylation enzyme Gal β1,4GlcNAc3-α-D-galactosyltransferase [α(1, 3)GT; EC2.4.1.51] [1] . This enzyme is active in the Golgi apparatus of cells and transfers galactose from the sugar-donor uridine diphosphate galactose (UDPgalactose) to the acceptor N-acetyllactosamine residue (Gal β1-4GlcNAc-R ) on carbohydrate chains of glycolipids and glycoproteins, to form gal epitope (Gala1, 3Galb1-4GlcNAc-R) [1] .
Gal epitope is completely absent in humans, apes, and Old World monkeys (monkey of Asia and Africa) because their genes encoding α(1, 3)GT have become inactivated in the course of evolution [2] , [3] . Since humans and Old World primates lack the gal epitope, they are not immunotolerant to it and produce anti-gal epitope antibodies (anti-Gal) throughout life in response to antigenic stimulation by gastrointestinal bacteria [4] and as many as 1% of circulating B cells are capable of producing this antibody [5] .
Anti-Gal forms a major immunological obstacle for xenotransplantation of nonprimate mammalian vascularized organs, such as porcine organs, into human recipients [6] . The binding of anti-Gal to gal epitopes expressed on glycolipids and glycoproteins on the surface of endothelial cells in donor organs leads to activation of the complement cascade and hyperacute rejection, and also plays important role in occurrence of complement-independent delayed xenograft rejection [6] . Anti-Gal also prevents the use of retroviral vectors propagated in mouse cells for gene therapy, because natural anti-Gal binds to gal epitopes on the viral envelope glycoproteins and induces the destruction of these viruses [7] .
In cancer research, studies on the immune response of tumor vaccines have indicated that a major prerequisite for the success of tumor vaccines is their effective uptake by antigen-presenting cells (APCs) and transportation of these APCs to the draining lymph nodes, where the processed and presented tumor-associated antigens (TAAs) activate tumor-specific naive T cells [8] . Galili et al [9] proposed that the immunogenicity of autologous tumor vaccines in human maybe augmented by engineering vaccinated tumor cells to express gal epitopes on membranes. Subsequent in situ binding of natural anti-Gal IgG molecules to these epitopes would result in the formation of immune complexes that target tumor vaccines for uptake by APCs via the interaction of the Fc portion of antiGal with Fcgreceptors on APCs. This hypothesis has been tested in vivo as well as in vitro [10] , [11] .
At present, a number of studies have suggested that human recombinant adenoviruses (rAdvs) are efficient vectors for the delivery of cloned genes to a variety of tumor cells and tissues [12] . Therefore, in the current study, a recombinant replicationdefective adenovirus that expresses the pig α(1, 3) GT gene was constructed. We evaluated the expression of gal epitope on the surfaces of several human tumor cell lines after adenoviral vector transduction.
MATERIALS AND METHODS

Cell culture
All cell lines were from Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). The 293 cells (Immortalized human embryonic kidney cells) and COS cells were cultured in Dulbecco's modified Eagle medium (DMEM; Gibco.BRL) supplemented with 10% heat-inactivated newborn bovine serum (NBS) in a humidified incubator with 5% CO 2 and 95% air at 37 o C. Human lung cancer cells (SPC-A-1), melanoma cells (A375), and stomach cancer cells (SGC-7901) were maintained in RPMI-1640 (Gibco.BRL) supplemented with 10% NBS. 293 cells were used for recombinant adenovirus transfection, amplification, and titration.
Construction of recombinant adenoviral vector expressing pig a(1, 3)GT gene
Plasmid pcDNA3-sGT1100 [13] was digested by Xho I and blunted with Klenow enzyme, and then digested by BamH I. the resulting 1.19 kb fragment of pig (1, 3)GT cDNA was subcloned into BamH I-EcoR V site in pBluescript II KS+/-to produce pKS-sGT, and then subcloned into the Hind III-Not I site in pAdCMV(s)-BGHpA containing 0 to 17 map units (mu) human type 5 adenovirus genome with a human CMV promoter, multicloning site and bovine growth hormone polyA signal inserted in the E1 region of viral genome to obtain the recombinant plasmid pAd-sGT (Fig 1) . This plasmid was cotransfected into 293 cells along with a plasmid pJM17 [14] containing most of the rightward sequences (3.7 to 100 mu) of human type 5 adenovirus genome with a partial deletion in the E3 region. The recombinant replication-defective adenovirus Ad5sGT was res- cued by homologous recombination (Fig 1) . The replicationdeficient recombinant adenoviruses, Ad5 β gal and Ad5null, used as the control throughout the study, have been previously described [15] . High titers of recombinant adenoviruses were amplified, purified, titered, and stored as previously described [16] .
Characterization of adenoviral vector expressing pig a(1, 3)GT gene
The genomic DNA extracted from Ad5sGT-infected 293 cells was digested with Hind III and the fragments were analyzed by agarose gel electrophoresis and Southern hybridization. COS cells were infected with Ad5sGT at multiplicity of infection (MOI) of 40. Flow cytometric analysis and the direct fluorescence of cell surface carbohydrate epitope on Ad5sGT-infected COS cells were performed with fluorescein isothiocyanate (FITC)-conjugated Bandeiraea simplicifolia isolectin B4 (BS-IB4) lectins (Sigma) specific for gal epitope.
Southern hybridization
Southern blot analysis was performed according to the standard procedures using pig (1, 3)GT cDNA released from pcDNA3-sGT1100 as probe. The probeswere labeled with -32 P dATP using Random primed DNA labeling kit (Boehringer Mannheim, GmbH, Germany). DNA fragments separated by agarose gel electrophoresis were transferred onto Hybond-N membranes (Amersham) by capillary transfer method and were subsequently hybridized with the radiolabeled probes. 
Flow cytometric analysis
Efficiency of recombinant adenovirus infection
Statistical analysis
Data in this study were expressed as means and standard deviations and analyzed by Student s t test.
RESULTS
Characterization of adenoviral vector express-
Expression of (1, 3)GT by recombinant adenovirus ing pig a(1, 3)GT gene Upon hybridization to pig α(1, 3)GT cDNA probe, a specific hybrid band was detected in Hind III-digested genomic DNAs from 293 cells infected by the recombinant adenovirus expressing pig α(1, 3)GT gene (Ad5sGT) (Fig 2A) , corresponding to about 5.3 kb fragment of viral DNA as predicted. These results demonstrated the incorporation of pig a(1, 3)GT cDNA into the adenoviral genome.
Since COS cells were demonstrated previously that no gal epitope was expressed on the cell membrane [17] , these cells were therefore used in this study to determine the expression of pig α(1, 3)GT gene incorporated in the adenoviral vector Ad5sGT. To verify transgene expression, COS cells were infected with Ad5sGT at 40 MOI. At 48 h after infection, the expression of α(1, 3)GT gene in Ad5sGT-infected COS cells was detected in both the direct immunofluorescence of cell surface carbohydrates ( Fig 2B) and flow cytometric analysis (Fig 2C) using the FITC-conjugated BS-IB4 lectin specific for gal epitope. These data display the efficacy of pig α(1, 3)GT gene expression in various cell types, driven by the CMV promoter contained in this adenoviral vector.
Recombinant adenovirus infection
Following infection with Ad5βgal, COS, SPC-A-1, SGC-7901 and A375 cells exhibited different efficacies of recombinant adenovirus infection. However, more than 90% of infectivity was achievable for all these cell lines at different optimum MOIs (Fig 3) . The optimum MOI was 40 for COS and SGC-7901 cells, 20 for A375 cells, and 45 for SPC-A-1 cells.
Expression of gal epitope on human tumor cells
To determine whether α(1, 3)GT expressed from Ad5sGT could effectively synthesize gal epitope on the membrane of human tumor cells, three tumor cell lines were analyzed. The results revealed that all the tumor cells infected with Ad5sGT expressed high level of gal epitope recognizable by BS-IB4 lectin on the cell membrane. In contrast, original tumor cells and Ad5null-infected tumor cells did not express gal epitope, as indicated by a lack of interaction with BS-IB4 lectin (Fig 4) .
Binding of human IgG and IgM natural antibodies to human tumor cells and complement activation after Ad5sGT infection
To determine whether expression of (1, 3)GT gene in human tumor cells could result in binding of human natural antibodies to cell surface, SGC-7901, SPC-A-1 and A375 cells were infected with Ad5sGT and Ad5null, respectively, and then incubated with 10% normal human serum (NHS). Rabbit anti-human IgG and IgM antibodies were used as second antibodies to detect the binding of human Igs to the cell surface. Flow cytometry was performed as described in Materials and Methods. As shown in Fig 5A, 
Effect of (1, 3)GT gene expression on expression of cell surface carbohydrates
To investigate whether the gal epitope expression could alter the expression of cell surface carbohydrates, the expression of cell surface carbohydrates, particularly those reacting with UEA-I, VVA, PNA and SBA lectins, on the surface of human tumor cells A375, SGC-7901 and SPC-A-1 was first determined by flow cytometry using FITC-conjugated lectins. The results revealed that all these tumor cell lines expressed the UEA-I, SBA, PNA and VVA lectin binding sites on the membrane at different levels (Tab 1). In the presence of gal epitope on tumor cell surface, the expression of UEA I lectin binding site, known as the blood group H antigen [18] which was expressed at the highest level on SGC-7901 cells, became decreased significantly. However, no effect of gal epitope expression on blood group H antigen expression was detected on A375 and SPC-A-1 cells which have rather lower level of blood group H antigen. The appearance of gal epitope also resulted in the decrease of VVA and PNA lectin binding sites on A375 and SGC-7901 cells, but not on SPC-A-1 trypan blue exclusion did not detect the significant difference in sensitivity to NHS-mediated lysis between human tumor cells with and without gal epitope.
Expression of gal epitope at different postinfection time points
In all three tumor cell lines, gal epitope levels were analyzed by flow cytometry using FITC-conjugated BS-IB4 lectin and were substantially high at 24 h after Ad5sGT infection. The gal epitope levels progressively increased with time and reached a maximum at 48 h in A375 and SPC-A-1 cells, and at 72 h in SGC-7901 cells. After these time points, gal epitope level decreased with time and became reduced to background level at 7 d after Ad5sGT infection (Fig 6) .
Tumor cell growth in vitro following gal epitope expression
The effect of gal epitope expression on the proliferative capacity of human tumor cells, including SGC-7901, SPC-A-1 and A375, was judged using MTT assay. The results showed that cells expressing gal epitope had the same proliferative capacity as their parent and the Ad5null-infected cells (Fig 7) . In addition, the morphology of these human tumor cells remained unchanged following gal epitope expression under light microscope.
DISCUSSION
Data in this study showed that human tumor cells SGC-7901, SPC-A-1 and A375 expressed high level of gal epitope on the membrane after Ad5sGT infection. In parallel, the ability of the binding of human IgG and IgM natural antibodies to gal epitope expressing cells was also enhanced. This suggested that the immune complexes of human tumor cells could be formed easily using human anti-Gal natural antibodies after Ad5sGT transduction. Link et al [19] has utilized gal epitope and anti-Gal antibodies reaction as a gene therapy for treatment of human cancer, in which human complement-mediated lysis of human melanoma A375 cells was induced by engineering melanoma cells to express gal epitope followed by incubation with NHS. In this study, we also examined the susceptibility of human tumor cells SGC-7901, SPC-A-1 and melanoma A375 to lysis by normal human serum following gal epitope expression. Cells were analyzed for gal epitope expression by flow cytometry and at the same time were incubated at 37 o C for 30 min in the presence of NHS at 10%, 20% and 40% concentrations respectively, and then the number of viable cells was counted by the method of trypan blue exclusion. However, no significant difference in susceptibility to lysis by NHS was observed in each of three tested human tumor cell lines between gal epitope expressing cells and its corresponding parental cells, although activation of complement was enhanced. Because complement-mediated cell lysis is inhibited by the complement regulatory proteins expressed on the cell surface [20] , no sensitization of these human tumor cells to NHS may be the results of high level expression of complement inhibitory molecules on these human tumor cells.
The biosynthesis of carbohydrate epitopes in cells is regulated by glycosyltransferases, which are responsible for the addition of carbohydrates to the oligosaccharide chain on glycolipids and glycoproteins in a sequential manner [21] . The newly introduced carbohydrate epitope had been observed to alter the expression of other carbohydrates. Gorelik et al [22] transfected murine melanoma cells, which do not express the gal epitope as well as carbohydrates reacting with SBA, PNA, and VVA lectins, with α(1, 3)GT cDNA. This resulted in the appearance of gal epitopes as well as carbohydrates reacting with SBA, PNA or VVA lectins. Appearance of SBA, PNA and VVA lectin binding carbohydrates in the α(1, 3)GT gene-transfected melanoma cells was suggested to be the results of reduction of cell membrane sialylation and subsequent unmasking of these carbohydrates due to the competition between α(1, 3)GT with α(2, 3) sialyltransferase or α(2, 6) sialyltransferase for the common acceptor N-acetyllactosamine in the Golgi apparatus [22] . In this study, unlike murine melanoma cells used in Gorelik's report [22] , human tumor cells SGC-7901, SPC-A-1 and A375 express carbohydrates reacting with SBA, PNA and VVA lectins on their surface but do not express gal epitope due to the inactivation of α(1, 3)GT gene in humans. After transduction with Ad5sGT, expression of carbohydrates reacting with PNA and VVA lectins on SGC-7901 and A375 cells was reduced to different degrees, but SBA and PNA lectin binding carbohydrates on SPC-A-1 cells were increased. The results reflected that expression of gal epitope has different effects on other carbohydrates expression depending on the features of carbohydrates on different cell types.
The α(1, 2) fucosyltransferase gene expression has been reported to resultin a drastic suppression of the gal epitope on mouse cells due to the enzymatic competition between the α(1, 3)GT and α(1, 2) fucosyltransferase for the common acceptor substrate [23] , [24] . In contrast to the mouse cells, SGC-7901, SPC-A-1 and A375 all express the blood group H antigen on the surface due to the α(1, 2) fucosyltransferase activity [18, 25] . Following gal epitope expression, the blood group H antigen was also reduced significantly on SGC-7901 cells. No changes in blood group H antigen expression on A375 and SPC-A-1 cells following gal epitope expression probably represented the limitation of H antigen which could be replaced by newly introduced gal epitopes. In this study, we also investigated whether expression of gal epitope could affect the growth of human tumor cells in vitro. The results showed that the expression of gal epitope on human tumor cells did not result in changes in cell growth in vitro as determined by MTT assays.
